Navigation Links
Aratana Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/13/2013

le future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of our current compounds, AT-001, AT-002 and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability  to obtain regulatory approval for our existing or future product candidates;  the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key scientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware l
'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aratana to Participate in Leerink Swanns November Management Access Days
2. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
3. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
10. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
11. Aratana Therapeutics names Wendy Yarno to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... For millions of overweight Americans, regular exercise remains a ... type 2 diabetes. However, a new study suggests ... for others, depending on their genes. "While physical ... as effective for everyone when it comes to preventing ... Ruth Loos, director of the Genetics of Obesity and ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a leading ... market, announced the presentation of clinical data for Avance® ... of the Hand (ASSH) 2014 Annual Meeting which took ... The ASSH Best Paper Award was given to ”Functional ... Large Gap Nerve Discontinuities: Outcomes From a National Registry ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 During ... on natural approaches to health including achieving hormonal ... nutrient deficiencies and detoxification. , ... follows: , Date: October 6-9, 2014, Location: Online ... register: http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 ... private insurance exchanges within three years, profoundly impacting health ... pleased to announce its upcoming virtual conference, “Private ... offer a valuable lesson on where private health insurance ... the industry is expected to look like when they ...
Breaking Medicine News(10 mins):Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2
... to face depression, says a study that suggests that such ... substantial illness with significant morbidity for patients and their families ... the health portal WebMd. , ,Lee S. Cohen ... Boston women aged 36 to 45 for up to six ...
... study in the April edition Journal of the American ... boost the number of children// who select a calcium-rich ... the amount of saturated fat consumed from calcium-rich beverages. ... three ethnically diverse elementary schools in Florida. The results ...
... Children who drink juice do not face the risk of ... of the juice in children’s diet and body mass index ... this conclusion. // ,According to foodconsumer.org, he ... mass index for their age and that children aged 12-18 ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... people were being failed by the NHS says a joint ... Commission for Social Care Inspection. // Elder abuse is hurting ... people are subject to patronising and thoughtless attitudes from some ... place to another, their meals are whisked away uneaten for ...
... men who were born with an "incurable" genetic disorder ... infections has been repaired with Gene therapy. // Sixteen ... the once severely ill patients show signs of complete ... that this latest success will lead to further operations ...
Cached Medicine News:Health News:Neglect of the Elderly by the Community 2Health News:Gene Therapy Helps To Cure 'Incurable' Illness 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: